A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Clinical trial NCT05258747 · COMPLETED

Trial details

NCT number: NCT05258747
Sponsor: Sandoz
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Ovarian Cancer Breast Cancer

Start date: 2022-04-07
Primary completion: 2022-10-20
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.